# Aptamer Group secures £360,000 contract with top 3 global pharma

- Link: https://www.directorstalkinterviews.com/aptamer-group-secures-360000-contract-with-top-3-global-pharma/4121219880
- Published: 2025-10-08T07:12:35+01:00
- Author: Amilia Stone

**Aptamer Group plc** (LON:APTA), the developer of next-generation synthetic binders
for the life sciences industry, has announced a major new development contract with
a top 3 global pharmaceutical company and continued strong commercial progress in
the first quarter of the financial year.

The new £360,000 fee-for-service development contract is to develop Optimer® binders
as targeted radiopharmaceuticals with potential applications in therapeutics. Aptamer
retains rights for future licensing revenues upon commercialisation, positioning
the Company for future downstream licensing and/or royalty revenue streams.

This programme will engineer Optimers targeting an undisclosed cancer target. Preliminary
work will develop tools for Positron Emission Tomography (PET) imaging with a view
to translating to therapeutic applications. The Optimer® platform offers advantages
for this application area, including enhanced tumour penetration, reduced immunogenicity,
and ease of chemical optimisation. The contract expands the application of the Company’s
Optimer® technology into the growing targeted radiopharmaceuticals market, valued
at $7.5 billion in 2025, and represents the second therapeutic modality under development
by Aptamer alongside targeted gene therapy.

**Commercial update**

Building on the £1.2 million revenue achieved in FY25, the Company has already secured
£315,000 in new contracts and project extensions for the current financial year.
These developments further position the Company for revenue growth in the current
year.

Including the new development contract for radiopharmaceutical development, Aptamer
has secured additional commitments totalling £675,000 in total contract value. Combined
with £350,000 of contract value carried over from FY25, this provides visibility
of approximately £1.03 million in contract value for the current period, with nine
months of the year remaining.

Aptamer’s sales pipeline remains robust and healthy, now standing at £3.4 million
for fee-for-service opportunities following the closure of the £675,000 in new deals
and subsequent replenishment through active prospects.

The £315,000 in further contracts and extensions signed in this financial year to
date include:

·      Two extensions with a top 5 global pharmaceutical company for work on an 
ELISA project.

·      The synthesis of a bulk amount of an enzyme inhibitor to support a licensing
deal under negotiation.

·      A therapeutic development agreement with Invizius to develop Optimer® binders
targeting complement system components for safer treatments for inflammatory conditions.

·      A range of smaller contracts across therapeutics, diagnostics, and research,
further diversifying the Company’s revenue streams.

This is not indicative of full-year performance, and the Company is not providing
formal guidance for FY26 at this time as contract timings, project completions, 
and revenue recognition can vary significantly across quarters due to the nature
of Aptamer’s business.

> **Dr Arron Tolley, Chief Executive Officer of Aptamer Group, said:** “This significant
> contract win with a top 3 global pharmaceutical company marks a key expansion 
> of our platform into targeted radiopharmaceuticals and potential therapeutics.
> This represents a value inflection point as Aptamer now has two potential therapeutic
> assets under development.
> “In addition to the smaller contracts and our therapeutic agreement with Invizius,
> Aptamer has an order book carried over from FY25, which provides £1.03 million
> in contract value visibility alongside our £3.4 million sales pipeline, providing
> a strong platform for FY26.”

Share on:
